Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Accrued outsourced manufacturing expenses

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept halo:AccruedOutsourcedManufacturingExpenses.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's accrued outsourced manufacturing expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's accrued outsourced manufacturing expenses?
Halozyme Therapeutics (HALO) reported accrued outsourced manufacturing expenses of $9.11M in Q1 2026.
How has Halozyme Therapeutics's accrued outsourced manufacturing expenses changed year-over-year?
Halozyme Therapeutics's accrued outsourced manufacturing expenses increased by 22.0% year-over-year, from $7.47M to $9.11M.
What is the long-term trend for Halozyme Therapeutics's accrued outsourced manufacturing expenses?
Over 3 years (2022 to 2025), Halozyme Therapeutics's accrued outsourced manufacturing expenses has grown at a -1.1% compound annual growth rate (CAGR), from $12.19M to $11.78M.